Core Viewpoint - Select Medical Holdings Corporation reported significant growth in revenue and income for the fourth quarter and full year ended December 31, 2025, alongside a positive business outlook for 2026 and the declaration of a cash dividend [1][2]. Financial Performance - For Q4 2025, revenue increased by 6.4% to $1,396.6 million from $1,312.6 million in Q4 2024 [1]. - Income from continuing operations before other income and expense surged by 203.1% to $63.9 million compared to $21.1 million in the prior year [1]. - Net income from continuing operations, net of tax, rose by 461.0% to $37.7 million, reversing a loss of $10.5 million in Q4 2024 [1]. - Adjusted EBITDA for Q4 2025 was $104.7 million, down from $116.0 million in Q4 2024 [1]. - Earnings per common share from continuing operations increased by 184.2% to $0.16, compared to a diluted loss per share of $0.19 in the prior year [1]. Annual Performance - For the year ended December 31, 2025, revenue grew by 5.1% to $5,452.8 million from $5,187.1 million in 2024 [1]. - Income from continuing operations before other income and expense increased by 25.3% to $336.2 million compared to $268.3 million in 2024 [1]. - Net income from continuing operations, net of tax, increased by 65.0% to $214.5 million from $130.0 million in the prior year [1]. - Adjusted EBITDA for the year was $493.2 million, down from $510.4 million in 2024 [1]. - Earnings per common share from continuing operations, net of tax, increased by 127.5% to $1.16, compared to $0.51 in 2024 [1]. Segment Performance - Critical Illness Recovery Hospital Segment: Q4 revenue increased by 4.9% to $629.7 million, with adjusted EBITDA rising by 5.3% to $66.4 million [2]. - Rehabilitation Hospital Segment: Q4 revenue increased by 15.2% to $339.2 million, with adjusted EBITDA increasing by 11.1% to $69.2 million [2]. - Outpatient Rehabilitation Segment: Q4 revenue increased by 1.6% to $324.6 million, but adjusted EBITDA fell to $11.2 million from $26.6 million in the prior year [2]. Business Outlook - For 2026, Select Medical expects revenue to be between $5.6 billion and $5.8 billion, with adjusted EBITDA projected between $520.0 million and $540.0 million [3]. - Fully diluted earnings per share are anticipated to range from $1.22 to $1.32 [3]. Dividend and Stock Repurchase - A cash dividend of $0.0625 per share was declared, payable on or about March 12, 2026 [2]. - The company authorized a stock repurchase program of up to $1.0 billion, with $96.5 million spent on repurchasing 6,375,512 shares in 2025 [2].

Key Takeaways CYH posted break-even Q4 EPS, topping estimates and improving from prior-year loss.Community Health Systems saw Q4 revenue fall 4.9% as admissions and patient days declined.CYH forecasts 2026 revenue of $11.6B-$12B and EBITDA of $1.34B-$1.49B, below 2025 levels.Community Health Systems, Inc. (CYH) reported break-even earnings per share in the quarter, outperforming the Zacks Consensus Estimate of a loss of 32 cents. The bottom line improved from a loss of 42 cents in the prior-year quarter.Net ...

First, I would like to say I am honored to speak to you today as CEO of Community Health Systems, Inc. I want to express my sincere gratitude to our Board of Directors for their support and their confidence in appointing Jason and myself to our permanent roles as CFO and CEO, respectively. I would also like to thank many of the people on this call for offering your support and congratulations, which has meant so much to me personally. And, of course, I want to acknowledge our employees and physicians and ev ...

Community Health Systems (NYSE:CYH) Q4 2025 Earnings call February 19, 2026 11:00 AM ET Company ParticipantsAnton Hie - VP of Investor RelationsJason Johnson - EVP and CFOKevin Hammons - CEOConference Call ParticipantsA.J. Rice - AnalystAndrew Mok - AnalystBen Hendrix - AnalystBrian Tanquilut - AnalystJason Cassorla - AnalystJosh Raskin - AnalystStephen C. Baxter - AnalystOperatorHello, everybody, and thank you for holding. Today's call will begin in five minutes. Once again, thank you for holding, and toda ...

Earnings Presentation 4th Quarter, 2025 February 18, 2026 Disclaimer Statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995 that involve risk and uncertainties. All statements in this presentation other than statements of historical fact, including statements regarding projections, expected operating res ...

Performance in Q4 2025 was driven by sequential margin expansion resulting from higher acuity, improved payer mix, and sustained cost controls. Management attributed growth in specific markets to targeted capital investments, such as ER expansions in Knoxville and a $10 million women's services investment in Birmingham. The company successfully reduced leverage from 7.4x to 6.6x year-over-year through a combination of operational improvements and the application of divestiture proceeds to debt reducti ...

NEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that it has filed a class action lawsuit against Ardent Health, Inc. (NYSE:ARDT) and certain of the Company’s senior executives for securities fraud after a significant stock drop resulting from potential violations of the federal securities laws. If you invested in Ardent Health, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/ardent-health-inc-class-act ...

Core Insights - Pediatrix Medical Group reported earnings of $0.40 per share for Q4 2025, with an Adjusted EPS of $0.50, reflecting solid same-unit revenue growth despite industry headwinds [1][2] - The company generated net revenue of $494 million for Q4 2025, a decrease from $502 million in the prior year, primarily due to practice dispositions [1][2] - For the full year 2025, Pediatrix reported revenue of $1.91 billion, down from $2.01 billion in 2024, but net income improved to $165.4 million from a net loss of $99.1 million in the previous year [2][3] Financial Performance - Q4 2025 - Adjusted EBITDA for Q4 2025 was $66 million, down from $68.7 million in Q4 2024, mainly due to higher same-unit expenses [1][3] - Net income for Q4 2025 was $34 million, compared to $30.5 million in Q4 2024, with a diluted share count of 84.4 million [1][3] - Same-unit revenue from net reimbursement-related factors increased by 6.7%, while patient service volumes decreased by 2.7% [1][2] Financial Performance - Full Year 2025 - Adjusted EBITDA for the year ended December 31, 2025, was $275.6 million, an increase from $224 million in 2024 [2][3] - Adjusted EPS for 2025 was $2.04, compared to $1.51 in 2024 [2][3] - Cash and cash equivalents at year-end 2025 were $375.2 million, up from $229.9 million in 2024 [2][3] Operational Highlights - Practice salaries and benefits expense for Q4 2025 was $348 million, slightly down from $349 million in the prior year [1][3] - General and administrative expenses increased to $65.7 million in Q4 2025 from $63.6 million in Q4 2024 [1][3] - Transformational and restructuring-related expenses decreased significantly to $5.9 million in Q4 2025 from $23.6 million in the prior year [1][3] Preliminary Outlook for 2026 - The company anticipates 2026 Adjusted EBITDA to be in the range of $280 million to $300 million [2][4]

Core Viewpoint - A class action lawsuit has been filed against Ardent Health, Inc. and its senior executives for securities fraud following a significant stock drop attributed to potential violations of federal securities laws [1][3]. Company Overview - Ardent Health, Inc. operates acute care hospitals and other healthcare facilities, with a focus on the collection of accounts receivable [4]. Allegations of Fraud - The lawsuit claims that Ardent Health misrepresented its process for determining the collectability of accounts receivable, stating it relied on "detailed reviews of historical collections," while in reality, it used a "180-day cliff" method to reserve accounts, leading to inflated receivable reports [4]. Stock Performance Impact - On November 12, 2025, Ardent Health disclosed a $43 million revenue decrease for the quarter and increased its professional liability reserves by $54 million, resulting in a stock price drop of $4.75 per share, or over 33%, from $14.05 to $9.30 [5]. Legal Proceedings - Investors have until March 9, 2026, to request to lead the case in the U.S. District Court for the Middle District of Tennessee, under the caption Postiwala v. Ardent Health, Inc., et al. [3].

作为省级重点中医专科，老年病科以专业实力筑牢老年健康根基。引进老年综合评估系统，多维度精准 定位患者健康问题，结合中医"杂合以治"理念，制定个性化方案；针对老年特有病症，科室善用经方汤 剂、益元膏等中药剂型，搭配耳部三联治疗等外治疗法，实现内服外治协同增效；配备经颅磁刺激仪、 平衡功能训练系统等先进设备，形成"中医辨证+现代康复"的双重保障，让传统医学在老年诊疗中焕发 新生，为老年特有病症提供针对性解决方案。 下一步，该院老年病科将以此次获评作为新起点，持续深耕中医特色优势，优化适老化服务细节，拓展 医养结合服务边界。以精湛的诊疗技术、便捷的服务流程、暖心的人文关怀，践行老年友善服务理念， 守护每一位老年人的健康与尊严。 本报讯 记者徐婕报道 近日，在云南省开展的2025年度老年友善医疗机构建设工作中，经多轮严格审 核，昆明市中医医院获评"2025年度老年友善医疗机构"。 针对老年患者就医的 "急难愁盼"，该院从流程、环境、保障多维度推进适老化改造。为80岁及以上老 年患者开通"银发绿色通道"，减免挂号诊查费并优先诊疗，大大缩短就医时长；门诊大厅一站式服务中 心整合全流程服务，自助缴费机与人工挂号、现金支付方 ...